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Abstract
Introduction: The purpose of this work was to establish and validate combined small animal positron emission
tomography - computed tomography (PET/CT) as a new in vivo imaging method for visualisation and
quantification of joint inflammation.
Methods: Signalling of radioisotope
18F labelled Fluorodeoxyglucose (
18F-FDG) injected in mice with glucose-6-
phosphate isomerase (G6PI)-induced arthritis was analysed by PET/CT. Accumulation of
18F-FDG in tissue was
quantified by PET measurement, whereas high definition CT delivered anatomical information. The fusion of both
images revealed in detail spatial and temporal distribution and metabolism of
18F-FDG.
Results: A distinct
18F-FDG signal could be measured by PET in carpal and tarsal joints, from mice with early or
established arthritis. In contrast, no accumulation of
18F-FDG was detectable before arthritis onset. Comparison of
18F-FDG joint uptake with histopathological evaluation revealed a significant correlation of both methods.
Conclusions: Small animal PET/CT using
18F-FDG is a feasible method for monitoring and, more importantly,
quantitative assessment of inflammation in G6PI-arthritis. Since it is possible to perform repeated non-invasive
measurements in vivo, not only numbers of animals in preclinical studies can markedly be reduced by this method,
but also longitudinal studies come into reach, e. g. for individual flare-up reactions or monitoring therapy response
in progressive arthritis.
Introduction
The current gold standard for the assessment of inflamma-
tion in small-rodent models of arthritis is histopathological
evaluation of joint sections. Apart from semiquantitative
grading, limitations of this method include the impossibil-
ity of performing in vivo or longitudinal studies and the
need for relatively large numbers of animals. Non-invasive
imaging techniques allowing an objective quantitative
assessment of inflammation would, therefore, be a most
welcome tool for arthritis research.
Positron emission tomography (PET), predominantly
using the radiopharmaceutical
18F-labelled fluorodeoxy-
glucose (
18F-FDG) as metabolic tracer, is a functional
in vivo imaging technique that is clinically used mainly for
tumor diagnosis, therapy monitoring, and experimental
cancer research.
18F-FDG is a glucose analog in which the
2’-OH has been replaced by
18F. Consequently,
18F-FDG
cannot be further metabolized after phosphorylation and
is trapped and enriched within the cell. This offers the
opportunity of a quantifiable
18F-FDG PET signal from
sites of pathological increased glucose metabolism in the
tissue (that is, sites of inflammation). In addition, glucose
metabolism is affected by proinflammatory tumor necrosis
factor-alpha (TNF-a) and characteristically increased in
inflamed tissue [1,2], making PET a potentially interesting
technique for the detection and quantification of inflam-
mation. Analyses of radioisotope-labelled FDG uptake
in vitro revealed a distinct accumulation in fibroblasts and
neutrophils, whereas resting macrophages incorporated
only small amounts [3]. Stimulation of cells with TNF-a
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any medium, provided the original work is properly cited.revealed a shift to strong glucose uptake in macrophages
and even more in fibroblasts, whereas accumulation in
neutrophils remained stable at the level of stimulated
macrophages. The accumulation of
18F-FDG in cells con-
tributing to synovial inflammation [4-6] could provide a
sensitive and non-invasive tool for visualization and quan-
tification of joint inflammation in vivo.
In rheumatoid arthritis (RA), only a few studies thus far
have examined the use of PET, proposing quantitative
18F-FDG PET as a promising technique to measure disease
activity and to monitor the efficacy of anti-inflammatory
drugs without restriction to morphology-based informa-
tion [7,8]. PET is also increasingly used in preclinical
research [3,9]. Since computed tomography (CT) has a
higher resolution than PET, one approach of modern ima-
ging systems is the combination of PET and CT. Thus, in
humans, the detailed morphological information provided
by CT can be used to localize the anatomical source of
PET signals exactly [10].
The goal of our work was to examine, in well-described
glucose-6-phosphate isomerase (G6PI)-induced murine
arthritis [11-17], whether
18F-FDG micro-PET/CT can be
used for the quantitative in vivo assessment of inflamma-
tion in acute and chronic stages of experimental arthritis.
To validate the method, results were systematically com-
pared with semiquantitative histopathological analyses.
Our findings revealed a linear and statistically significant
correlation of
18F-FDG PET/CT quantification and histo-
pathological evaluation of inflammatory experimental
arthritis. In the field of arthritis research, small-animal
PET/CT imaging thus offers new opportunities for a quan-
titative assessment of inflammation and even can be per-
formed in vivo.
Materials and methods
Glucose-6-phosphate isomerase-induced arthritis
DBA/1 mice were bred at the animal facility of Jena Uni-
versity (Jena, Germany). All animal studies were approved
by the local commission for animal protection (registered
number 02-045/08). Arthritis was induced as described
e l s e w h e r e[ 1 1 ] .I nb r i e f ,D B A / 1m i c ew e r ei m m u n i z e d
subcutaneously with 400 μg of recombinant human G6PI
in emulsified complete Freund’s adjuvant (Sigma-Aldrich,
Taufkirchen, Germany). Macroscopic evaluation of arthri-
tis was performed as previously described [11]. A score of
0 indicates no macroscopically recognizable signs of
arthritis, 1 indicates swelling and redness, 2 means strong
swelling and redness, and 3 indicates massive swelling and
redness. For the total clinical score per animal, results
from all paws were summed. In the experiment assessing
practicability of small-animal PET/CT in monitoring ther-
apeutical intervention, 150 μg of soluble tumor necrosis
factor receptor (sTNFR) fusion protein (etanercept;
Wyeth, Münster, Germany) in 100 μL of saline or saline
alone as control was daily administered intraperitoneally,
beginning 1 day after immunization.
Histopathological assessment of glucose-6-phosphate
isomerase-induced arthritis
For histopathological examinat i o n ,m i c ew e r es a c r i f i c e d
immediately after PET/CT measurement. Sections of fixed
and decalcified joints were evaluated by a pathologist.
Arthritis severity of each paw was graded according to a
histopathological scoring system, with consideration of
acute and chronic inflammatory parameters as described
before [18]. In brief, acute inflammation reflects pathologi-
cal alterations by infiltration of neutrophil granulocytes in
the synovial membrane (0 = no, 1 = slight, 2 = moderate,
and 3 = severe) and by exudate (0 = no, 1 = slight, 2 =
moderate, and 3 = severe), with an additional scoring for
the presence of fibrin and the affection of periarticular tis-
sue. The maximal possible value per paw for acute inflam-
mation according to this scoring was 8. Chronic
inflammation denotes pathological alterations by synovial
hyperplasia, infiltration of mononuclear cells, and fibrosis
(0 = no, 1 = slight, 2 = moderate, and 3 = severe), with a
maximum of 9. Total inflammation score reflects the sum
of acute and chronic inflammation in the joint and periar-
ticular tissue. For individual histopathological arthritis eva-
luation, scores from all paws were summed.
Positron emission tomography-computed tomography
in vivo imaging
A Siemens Inveon small-animal multimodality PET/CT
system (Preclinical Solutions; Siemens Healthcare Mole-
cular Imaging, Knoxville, TN, USA) was used for in vivo
imaging. This PET/CT system is characterized by the
combination of two independently operating PET and
CT scanners. Radial, tangential, and axial resolutions at
the center of the field of view of the PET module are
better than 1.5 mm [19,20]. PET acquisitions were car-
ried out with default settings of coincidence timing win-
dow of 3.4 ns and energy window of 350 to 650 keV.
Images were reconstructed using Fourier rebinning and
the two-dimensional ordered-subset expectation maxi-
mization (OSEM 2D) algorithm. Attenuation was cor-
rected on the basis of the CT measurements. The CT
module consists of a cone beam micro-x-ray source
(50-μm focal spot size) and a 2,048 × 3,072 pixel x-ray
detector. Our standard micro-CT imaging protocol used
80 kVp at 500 μA, 360° of rotation, and 200 projections
per bed position. Micro-CT images were reconstructed
using a Shepp-Logan filter and cone-beam filtered back-
projection.
Quantitative analysis of
18F-FDG accumulation in the
period from 40 to 60 minutes after injection was enabled
by the image fusion technology of Siemens Inveon
Research Workplace software 2.2 (Siemens Healthcare
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dataset was divided in 39 time frames; otherwise, data
from 40 to 60 minutes after
18F-FDG injection were ana-
lyzed in a single time frame. Volumes of interest (VOIs)
used for quantification of fore and hind limb inflammation
were 2.5 and 3.1 mm
3, respectively. Inflammatory tissue
uptake of the glucose analog was measured as percentage
of injected dose per gram (% ID/g). Three-dimensional
(3D) surface rendering (SR) of areas with increased
18F-FDG uptake was carried out with PMOD software
3.0 (PMOD Technologies Ltd., Zurich, Switzerland) by
means of SR techniques using an 8% ID/g threshold. Mice
were anesthetized with 1.5% to 2% vaporized isoflurane
(DeltaSelect, Dreieich, Germany) in oxygen (1.5 L/minute)
to prevent animal movement and reduce imaging artefacts.
18F (half-life 109 minutes)-labelled FDG (Eckert & Ziegler,
Berlin, Germany) with an activity of 9.6 ± 0.6 MBq was
injected intravenously in the lateral tail vein.
Statistical analysis
Statistical differences between groups were evaluated
using the non-parametric Mann-Whitney U test. Mean
scores of fore and hind limbs or individual total scores
as the sums of all paws were used for analyses of rela-
tionships between histopathological parameters and
18F-FDG uptake (Spearman test). Statistical significance
was accepted for P values of less than 0.05 (*P < 0.05;
**P < 0.01; ***P < 0.001). All calculations were per-
formed using the software package SPSS version 16.0
(SPSS Inc., Chicago, IL, USA). In bar charts and text,
data are presented as arithmetic mean and standard
error of the mean.
Results
Histopathological assessment of arthritis severity
To examine the usability of state-of-the-art small-
animal PET/CT molecular imaging as an objective
method to quantify inflammation in experimental
arthritis research, severity of inflammation was ana-
lyzed at six different time points (days 2, 6, 9, 13, 21,
and 35) in the course of G6PI-induced arthritis, using
both micro-PET/CT and histology. Histopathological
assessment of the degree and components of immune
cell infiltration, synovial hyperplasia, and exudate in
arthritic joints enabled a semiquantitative scoring of
experimental arthritis severity (Figure 1a). Histology
revealed no pathological changes in joints and periarti-
cular joint tissue 2 and 6 days after G6PI immuniza-
tion (Figure 1b). At day 9, histopathological signs of
inflammation coincided with the onset of clinical
arthritis. Total individual scores as the sum of acute
and chronic parameters revealed a maximum of arthri-
tis severity at days 13 (24.8 ± 0.6) and 21 (23.9 ± 1.4)
and a subsequent decrease at day 35 (8.1 ± 1.9).
Scoring of macroscopically visible signs of arthritis
(redness and swelling) showed a similar course of
experimental arthritis severity (Figure 1c). The first
clinical signs appeared at day 9 (1.7 ± 0.6), and the
maximal clinical score (8.9 ± 0.5) was obtained at day
13. Clinical signs of arthritis were attenuated at day 21
(4.9 ± 0.4) and day 35 (2.4 ± 0.2).
Small-animal positron emission tomography/computed
tomography molecular imaging
Scanning of mice with micro-PET/CT generated high-
resolution 3 D images with information on temporal and
spatial biodistribution of
18F-FDG, reflecting the intensity
of tissue glucose metabolism. Precise anatomical localiza-
tion of VOIs was given by high-resolution CT imaging
(Figure 2a). The combination of PET and CT data
enabled detailed visualization of
18F-FDG signalling in
Figure 1 Histopathological and macroscopical evaluation of
glucose-6-phosphate isomerase (G6PI) arthritis severity. (a)
Acute murine G6PI-induced arthritis (day 13) provokes a massive
accumulation of mainly polymorphonuclear cells (right arrow) and
induces erosive processes (left arrow). Hematoxylin-and-eosin
staining at original magnifications of ×40 and ×400 is shown. B,
bone; C, cartilage; CI, cellular infiltrate; M, muscle. (b)
Histopathological semiquantitative assessment of paw sections
revealed a maximum of acute inflammation 13 and 21 days after
arthritis induction, whereas chronic inflammation parameters were
present past day 13. Total inflammation as the sum of acute and
chronic parameters was at a maximum at days 13 and 21 and
decreased at day 35 (n = 6 to 9 per time point). (c) Macroscopic
scoring of paw swelling showed a maximum of inflammation at day
13 after experimental arthritis induction and gradual decreases at
days 21 and 35.
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18F-FDG reached heart and lung via
the vena cava within the first 0- to 10-second time frame
after injection and subsequently was distributed in the
gastrointestinal tract and cranially via the carotid arteries.
Before arthritis onset (day 2), tracer enrichment was
restricted to tissue with high basal metabolic activity (in
particular, heart muscle and eyes) and organs of the
excretory system (kidneys and bladder; Figure 2c; Addi-
tional file 1). In acute experimental arthritis at day 13,
additional hot spots of
18F-FDG signalling could be
detected in the joints of fore and hind paws, indicating a
specific
18F-FDG uptake in inflamed joints (Figure 2d;
Additional file 2).
Accumulation of
18F-FDG in joints
Swelling and erythema of paws are characteristic clinical
features of acute G6PI-induced arthritis (Figure 3a).
18F-FDG accumulation measured by micro-PET/CT
revealed hot spots of inflammatory metabolic activity in
wrist and ankle joints and a less intense inflammation of
smaller distal joints. SR of PET/CT data using thresholds
(shown is 8% ID/g, according to the level of
18F-FDG joint
accumulation in acute G6PI arthritis) enabled a fusion-
based 3 D visualization of morphological structures and
regions, where
18F-FDG was enriched because of inflam-
matory processes. Kinetic analysis of
18F-FDG signalling in
joints before G6PI immunization (Additional file 3) and at
the stage of acute inflammatory arthritis (day 15; Addi-
tional file 4) revealed a beginning of
18F-FDG accumula-
tion approximately 5 minutes after injection (Figure 3b).
In arthritic joints,
18F-FDG uptake was still slightly
increasing 60 minutes after tracer injection. In healthy
joints, negligible tracer enrichment occurred during the
initial 20 minutes after injection, followed by a slight
decline. In arthritic animals, percentages of injected radioi-
sotope activities in the joint regions were between 8% and
15% ID/g, whereas tracer uptake in the same joints was
around 1% to 3% ID/g before immunization. Therefore,
differences in
18F-FDG uptake of arthritic and healthy
joints were pronounced, could be attributed to joint tissue
glucose metabolism changes caused by pathogenesis of
G6PI-induced arthritis, and could easily be quantified by
small-animal PET/CT techniques.
Repeated carpal and tarsal inflammation assessment in
t h es a m ea n i m a l sb y
18F-FDG PET measurements at
four time points (unimmunized and days 9, 15, and 22)
Figure 2
18F-labelled fluorodeoxyglucose (
18F-FDG) positron emission tomography/computed tomography (PET/CT) imaging in
experimental arthritis. (a) High-resolution CT provided detailed anatomical information of skeletal elements for accurate allocation of PET
signalling. (b) Rapid
18F-FDG biodistribution via blood circulation in a time frame 0 to 10 seconds after tail vein injection, visualized by PET and
CT image fusion. (c) PET imaging of mice before arthritis onset (day 2) revealed enrichment of
18F-FDG in tissue and organs (in particular, heart,
bladder, kidneys, and eyes). (d) Acute inflammatory arthritis (day 13) caused additional accumulation of
18F-FDG at sites of pathological increased
glucose metabolism (that is, inflamed carpal and tarsal joints) (arrowheads).
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(Figure 3c). Both the clinical scores (data not shown)
and the levels of carpal and tarsal
18F-FDG joint uptake
(Figures 3c and 4) were similar in those mice that
underwent small-animal PET/CT examination
Figure 3 Accumulation of
18F-labelled fluorodeoxyglucose
(
18F-FDG) in paws of DBA/1 mice with glucose-6-phosphate
isomerase (G6PI)-induced arthritis. (a) Clinical polyarthritis is
characterized by swelling and redness of paws. Enhanced glucose
metabolism of inflamed tissue caused an increased uptake and
subsequent enrichment of
18F-FDG in carpal and tarsal joints of
arthritic mice, visualized by high-resolution positron emission
tomography/computed tomography (PET/CT) imaging. Surface-
rendering (SR) of data using an 8% injected dose per gram
threshold allowed three-dimensional visualization of tissue with
pathological increased glucose metabolism. (b) Quantification of
accumulated
18F-FDG as a percentage of injected dose per gram
(% ID/g) within 0 to 60 minutes after injection.
18F-FDG enrichment
over time in left (L) and right (R) carpal and tarsal joints in an
exemplary mouse before immunization with G6PI (black symbols)
(that is, before pathological changes occurred) and increased
18F-FDG joint accumulation in the same animal at the stage of
acute inflammatory G6PI-induced arthritis at day 15 after
immunization (white symbols) are shown. (c) Repeated
18F-FDG
PET/CT in vivo determination and quantification of disease severity
in carpal (C) and tarsal (T) joints in the same mice 2 days before
and 9, 15, and 22 days after arthritis induction (n = 5).
Figure 4 Quantification of
18F-labelled fluorodeoxyglucose
(
18F-FDG) joint uptake in progressive arthritis. Inflammatory
metabolic effects of arthritis differing from
18F-FDG accumulation in
normal joint tissue are seen above an arbitrary baseline of 2% of
injected dose per gram. (a) Onset of clinical arthritis at day 9
resulted in a significant increase of
18F-FDG signalling in the fore
limb carpal joints with a maximum at day 13 and a subsequent
decreased
18F-FDG uptake in parallel to declining inflammation at
days 21 and 35 (n = 6 to 9 per time point). (b) Hind limb arthritis
progression reflected by
18F-FDG signalling in the tarsal joint,
coinciding with carpal joint signalling. % ID/g, percentage of
injected dose per gram. *P < 0.05; **P < 0.01; ***P < 0.001.
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only once and then employed for histopathological eva-
luation of arthritis.
In vivo quantification of joint inflammation by
18F-FDG
positron emission tomography/computed tomography
To analyze the usefulness of micro-PET/CT imaging for
monitoring severity of inflammatory arthritis,
18F-FDG
uptake in paws from a total of 42 mice at 6 different time
points of experimental disease was quantified. In joint tis-
sue without pathological changes (days 2 and 6), mean
accumulation of
18F-FDG in fore (Figure 4a) and hind
(Figure 4b) limbs was below 2% ID/g, the level of
18F-FDG
accumulation over time in joints of healthy animals before
induction of experimental disease (Figure 3b). At the onset
of clinical arthritis at day 9, emerging inflammation was
associated with an increase of glucose metabolism and
induced a significant increase of
18F-FDG uptake com-
pared with day 2 (carpal: P = 0.0002; tarsal: P = 0.02).
Mean values of % ID/g were 3.8 ± 0.57 in carpal and 2.4 ±
0.55 in tarsal joints.
18F-FDG uptake was further increased
at the peak of acute arthritis at day 13 (carpal: 9.2 ± 0.38;
tarsal: 12.7 ± 0.40), followed by subsequent decreases at
day 21 (carpal: 7.1 ± 0.39; tarsal: 7.6 ± 0.66) and day 35
(carpal: 3.9 ± 0.29; tarsal: 4.4 ± 0.46). Hence, PET data
revealed a 4- to 10-fold increase of
18F-FDG joint uptake
in inflammatory stages of arthritis. Interestingly,
18F-FDG
uptake revealed significant (P = 0.001; Figure 4a,b) deviat-
ing metabolic activity between days 13 and 21, demon-
strating a reduced inflammatory activity at day 21,
whereas histopathological assessment showed no
difference of arthritis severity in these groups (P =0 . 7 ;
Figure 1b). This reduced inflammation activity measured
by PET/CT at day 21 was confirmed by macroscopical
arthritis assessment (P = 0.001; Figure 1c).
Histopathological evaluation correlates significantly with
positron emission tomography quantification
To validate the method and to determine whether
18F-FDG uptake was correlated with histopathological
changes in arthritis, we performed correlation analysis
of individual quantitative PET results with semiquantita-
tive clinical and histopathological scoring data. Indivi-
dual
18F-FDG PET/CT quantification of inflammation
severity correlated significantly with macroscopic clinical
scoring (Figure 5a). Furthermore, there were significant
correlations of
18F-FDG uptake and histopathological
data assessment regarding scoring of acute, chronic, and
total inflammation (Figure 5b-d). Animals that scored in
t h eu p p e rr a n g eo ft h eh i s t o p a t h o l o g i c a la r t h r i t i si n d e x
also achieved maximum values in PET analysis. Interest-
ingly, arthritis severity in animals with maximal histo-
pathological scoring was further differentiated by
18F-
FDG PET/CT technique. This means that 25% of the
animals with the highest histopathological scores ranged
in the top 12% of the total bandwidth of histopathologi-
cal scoring. In contrast, assessment of inflammation by
PET/CT enabled a more refined staging. Here, the 25%
of the animals that showed the strongest
18F-FDG accu-
mulation in the joints covered the top 38% of the total
range of
18F-FDG uptake. For carpal and tarsal joints
and for joints total, correlations of
18F-FDG uptake and
histopathological assessment were highly significant
(Table 1). These significant correlations of both methods
demonstrate that small-animal PET/CT is a reliable
imaging method for in vivo quantification of inflamma-
tory arthritis.
18F-FDG positron emission tomography/computed
tomography and histopathological assessment in
monitoring therapeutic intervention
Experimental modulation of inflammation is an impor-
tant aim of arthritis research. To examine the usability of
small-animal PET/CT to monitor the outcome of a thera-
peutic intervention, G6PI-immuized mice were injected
with human sTNFR (etanercept) or saline. We quantified
18F-FDG enrichment in the joints of treated and control
mice by PET/CT and found a significant 4.9-fold
decrease of total
18F-FDG uptake in sTNFR (etanercept)-
treated arthritic mice (Figure 5e). Comparable results
were obtained using histopathological assessment of ther-
apeutic intervention (Figure 5f). The correlation coeffi-
cient of histopathological assessment and
18F-FDG
uptake was 0.862, whereas a P value of less than 0.002
revealed statistical significance of correlation of both
methods. Thus, PET/CT is a convenient technique for
monitoring treatment modalities in experimental arthri-
tis, even with small numbers of animals.
Discussion
PET data have been shown to correlate with clinical and
sonographic parameters in studies on patients with RA
[7,8]. The use of in vivo imaging techniques, including
PET, in murine models of arthritis has been hindered by
the reduced dimensions of the subjects of study. Here,
we used a small-animal PET/CT system to assess arthri-
tis severity in mice. This combination of PET with high-
definition CT in a single device allows the exact 3 D
anatomical localization of PET signals (that is,
18F-FDG
accumulation in the tissue). Moreover, combined PET
and CT imaging also allows the use of CT data to cor-
rect for tissue attenuation of PET signals. Our findings
demonstrate the feasibility and usefulness of
18F-FDG
joint uptake for objective in vivo quantification of syno-
vial inflammation in the course of G6PI-induced arthri-
tis. Whereas histopathological evaluation inevitably
requires sacrificing animals and therefore restricts the
complete data range of individual arthritis progression
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18F-FDG PET/CT allows repeated
investigations of the same subjects. This not only drasti-
cally reduces the number of animals required for a
study but also offers the appealing possibility of longitu-
dinal analyses within the same animal. Furthermore,
in vivo imaging increases statistical quality of data in
treatment studies because the status of an animal before
and after disease-modulating intervention can be
compared directly. Therefore, combined PET/CT using
18F-FDG as a tracer is a new and powerful tool to quan-
tify experimental joint inflammation non-invasively and
accurately in vivo.
Another non-invasive technique, thermal signature ana-
lysis, has been used to analyze rat rather than mouse
arthritis models [21]. Gait analysis, which has been per-
formed in both rat and mouse models, provides indirect
Figure 5 Coherence of
18F-labelled fluorodeoxyglucose (
18F-FDG) uptake and clinical and histopathological assessment of
inflammatory arthritis and use of
18F-FDG positron emission tomography/computed tomography for evaluation of therapeutical
intervention. (a) Clinical assessment of experimental arthritis was correlated with
18F-FDG enrichment at days 2, 6, 9, 13, 21, and 35 after arthritis
induction (n = 42). (b) Regression analysis of acute inflammation and
18F-FDG uptake evidenced a significant correlation of both parameters. (c)
Chronic inflammation also significantly correlated with
18F-FDG signalling. (d) Histopathological scoring of total inflammation as the sum of
acute and chronic inflammation showed a significant correlation with
18F-FDG uptake. (e)
18F-FDG uptake as a measure of inflammatory arthritis
activity in arthritic mice treated with soluble tumor necrosis factor receptor (sTNFR) (etanercept) is significantly reduced compared with
untreated controls in the acute stage of arthritis (**P = 0.009; n = 5 per group). (f) Histopathological assessment of diminished (**P = 0.008)
arthritis severity in the same mice coincided with
18F-FDG uptake. % ID/g, percentage of injected dose per gram.
Table 1 Statistical analysis of correlations of
18F-FDG joint uptake referred to histopathological and clinical evaluation
of inflammatory arthritis (Spearman test)
18F-FDG uptake, percentage of injected dose per gram
Carpal joints Tarsal joints Joints total
Correlation P value Correlation P value Correlation P value
Histological score
Inflammation
Acute 0.841 < 0.0001
a 0.857 < 0.0001
a 0.842 < 0.0001
a
Chronic 0.697 < 0.0001
a 0.796 < 0.0001
a 0.740 < 0.0001
a
Total 0.903 < 0.0001
a 0.904 < 0.0001
a 0.894 < 0.0001
a
Clinical score 0.938 < 0.0001
a 0.935 < 0.0001
a 0.929 < 0.0001
a
aHighly significant correlations.
18F-FDG,
18F-labelled fluorodeoxyglucose.
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mation [22,23]. The reduced need to sacrifice animals for
preclinical arthritis studies, the option to perform intra-
individual longitudinal studies, and the fact that quantita-
tive evaluation of inflammation is obtained faster with
PET/CT than with histopathological examinations all
encourage the use of PET/CT.
In contrast to histopathology,
18F-FDG PET/CT cannot
reveal the exact cellular composition of inflammatory
infiltrates. However, the necessity to acquire this infor-
mation depends upon the specific question of the study
and therefore is only casually addressed in experimental
arthritis studies in detail. Moreover, this shortcoming of
18F-FDG PET/CT is compensated by functional knowl-
edge and an increased range of values. First, histopatho-
logical assessment gives information about the number of
cells present at the site of inflammation, whereas
18F-FDG PET/CT gives information about metabolic
activation of these cells. This difference facilitates the
early detection of arthritis resolution. In our experiments,
this is exemplified by the deviance in G6PI arthritis
assessment at day 21 by using histology or PET/CT and
macroscopical evaluation. Second, even among mice with
maximal scores in semiquantitative histopathological
assessment,
18F-FDG PET/CT still showed quantitative
differences and thus enhanced discernability. Another
aspect of
18F-FDG is the reduction of methodological
variability since approval as a nuclear medicinal product
for humans guarantees a constant quality of the agent
and therefore reproducibility of data.
In regard to CT images in small-animal PET/CT
hybrid systems, only a small technological step in image
resolution is necessary to use CT data not only for gain-
ing anatomical information but, beyond that, to assess
inflammation and erosive processes in a single in vivo
data acquisition, extending the usefulness of this sophis-
ticated molecular imaging technique. The use of PET/
CT is not restricted to
18F-FDG or glucose metabolism.
In human autoimmune diseases, the approaches of
other imaging techniques, in particular scintigraphy,
using radiolabelled antibodi e so rd r u g sf o rs t a g i n ga n d
therapy decision-making, increasingly attracted interest
[24,25]. Therefore, other forms of small-animal PET/CT
application worth further developmental work are loca-
lizing targets of therapeutical monoclonal antibodies in
situ, if these were labelled with radioisotopes, and the
possibility of revealing the presence or expression level
of specific receptors correlated with disease in inflam-
matory regions [26-28].
Conclusions
In the current studies, we evaluated, for the first time,
the use of combined
18F-FDG PET/CT for in vivo
quantification of inflammatory conditions in
experimental murine arthritis. Robust statistical ana-
lyses at various time points of arthritis progression
showed a highly significant correlation to histopatholo-
gical inflammation assessment, proposing
18F-FDG
small-animal PET/CT as a feasible tool for preclinical
arthritis research. In addition to monitoring efficacy of
anti-inflammatory drugs, it offers the possibility of per-
forming large-scale animal studies including repeated
in vivo examinations. Next to objective quantification
of inflammation, information about synovial metabolic
activity, and an increased discernability of individual
disease severity, this is a major advantage of this new
and promising imaging technique, enabling a consider-
able contribution to the claim of reducing animal
numbers in experiments.
Additional material
Additional file 1:
18F-FDG joint accumulation before onset of
experimental arthritis (day 2). Injected
18F-FDG was enriched in tissues
with a high basal glucose metabolism and in organs of the excretory
system (heart muscle, eyes, bladder and kidneys), but not in extremities.
Three dimensional view of
18F-FDG signalling 60 min post tracer
injection. AVI video format.
Additional file 2:
18F-FDG joint accumulation in acute experimental
arthritis (day 13). Onset of experimental arthritis induced distinct
18F-FDG enrichment in joint regions affected by inflammation. Three
dimensional view of
18F-FDG signalling 60 min post tracer injection. AVI
video format.
Additional file 3: Kinetic of
18F-FDG uptake before onset of
experimental arthritis. Tail vein injected tracer was rapidly distributed in
the whole body and subsequently accumulated in the heart muscle and
in the bladder. Coronal view of
18F-FDG signalling 0-60 min post
injection. AVI video format.
Additional file 4: Kinetic of
18F-FDG uptake in acute experimental
arthritis. Besides tracer accumulation in the heart muscle and in the
bladder, under inflammatory conditions carpal and tarsal joints were
additional hot spots of
18F-FDG enrichment. Coronal view of
18F-FDG
signalling 0-60 min post injection. AVI video format.
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glucose-6-phosphate isomerase; PET: positron emission tomography; RA:
rheumatoid arthritis; SR: surface rendering; sTNFR: soluble tumor necrosis
factor receptor; TNF-a: tumor necrosis factor-alpha; VOI: volume of interest.
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